The hemophilias—from royal genes to gene therapy
PM Mannucci, EGD Tuddenham - New England Journal of …, 2001 - Mass Medical Soc
Of the various types of hemophilia, the most common of these lifelong bleeding disorders
are due to an inherited deficiency of factor VIII or factor IX (Table 1). The genes for these …
are due to an inherited deficiency of factor VIII or factor IX (Table 1). The genes for these …
Hemophilia a
LW Hoyer - New England Journal of Medicine, 1994 - Mass Medical Soc
The dramatic hemorrhages, the effect of the disease on history through its presence in
Queen Victoria's descendants, and the devastating role of therapeutic concentrates in the …
Queen Victoria's descendants, and the devastating role of therapeutic concentrates in the …
Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice
The antibody Fc region regulates antibody cytotoxic activities and serum half-life. In a
therapeutic context, however, the cytotoxic effector function of an antibody is often not …
therapeutic context, however, the cytotoxic effector function of an antibody is often not …
Real time quantitative PCR.
CA Heid, J Stevens, KJ Livak, PM Williams - Genome research, 1996 - genome.cshlp.org
We have developed a novel" real time" quantitative PCR method. The method measures
PCR product accumulation through a dual-labeled fluorogenic probe (ie, TaqMan Probe) …
PCR product accumulation through a dual-labeled fluorogenic probe (ie, TaqMan Probe) …
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields, AK Namenuk, K Hong, YG Meng… - Journal of Biological …, 2001 - ASBMB
Immunoglobulin G (IgG) Fc receptors play a critical role in linking IgG antibody-mediated
immune responses with cellular effector functions. A high resolution map of the binding site …
immune responses with cellular effector functions. A high resolution map of the binding site …
Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc
EE Idusogie, LG Presta… - The Journal of …, 2000 - journals.aai.org
Rituxan (Rituximab) is a chimeric mAb with human IgG1 constant domains used in the
therapy of non-Hodgkin's B cell lymphomas. This Ab targets B cells by binding to the cell …
therapy of non-Hodgkin's B cell lymphomas. This Ab targets B cells by binding to the cell …
Charge variants in IgG1: isolation, characterization, in vitro binding properties and pharmacokinetics in rats
Antibody charge variants have gained considerable attention in the biotechnology industry
due to their potential influence on stability and biological activity. Subtle differences in the …
due to their potential influence on stability and biological activity. Subtle differences in the …
Structure of the secretory immunoglobulin A core
N Kumar, CP Arthur, C Ciferri, ML Matsumoto - Science, 2020 - science.org
Secretory immunoglobulin A (sIgA) represents the immune system's first line of defense
against mucosal pathogens. IgAs are transported across the epithelium, as dimers and …
against mucosal pathogens. IgAs are transported across the epithelium, as dimers and …
Massively parallel single-cell B-cell receptor sequencing enables rapid discovery of diverse antigen-reactive antibodies
LD Goldstein, YJJ Chen, J Wu, S Chaudhuri… - Communications …, 2019 - nature.com
Obtaining full-length antibody heavy-and light-chain variable regions from individual B cells
at scale remains a challenging problem. Here we use high-throughput single-cell B-cell …
at scale remains a challenging problem. Here we use high-throughput single-cell B-cell …
A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression
LJ Suva, GA Winslow, REH Wettenhall, RG Hammonds… - Science, 1987 - science.org
Humoral hypercalcemia of malignancy is a common complication of lung and certain other
cancers. The hypercalcemia results from the actions of tumor factors on bone and kidney …
cancers. The hypercalcemia results from the actions of tumor factors on bone and kidney …